对于需要合用质子泵抑制剂(PPI)的RET融合阳性晚期非小细胞肺癌患者,美国说明书未要求普拉替尼因PPI额外错时,普拉替尼仍须空腹服用;塞普替尼应避免合用PPI,确需合用时须随餐。合用PPI时,普拉替尼的额外给药限制少于塞普替尼。[1,2] ARROW最终分析中,部分患者接受普拉替尼后颅内病灶缓解;AcceleRET-Lung一线随机Ⅲ期研究的普拉替尼组和含铂标准治疗组中位无进展生存期分别为18.7个月和9.0个月。[3,4]
美国GAVRETO说明书(2025年12月修订)记载,普拉替尼与胃酸降低药合用时,未观察到有临床意义的药代动力学变化,未要求因PPI额外错时服用。高脂餐可增加普拉替尼暴露,普拉替尼仍须空腹服用,服药前至少2小时、服药后至少1小时不进食。[1]
EMA评估报告记载,在健康受试者研究中,普拉替尼与艾司奥美拉唑(esomeprazole)合用后,峰浓度(Cmax)下降25%、总暴露量(AUC)下降15%,评估为无临床显著影响。[5]
美国RETEVMO说明书(2026年7月修订)要求塞普替尼避免与胃酸降低药合用;确需合用PPI时,塞普替尼须随餐服用。确需与H?受体拮抗剂合用时,塞普替尼须在其给药前2小时或给药后10小时服用;确需与局部抗酸药合用时,须在抗酸药给药前2小时或给药后2小时服用。[2]
LIBRETTO-001和LIBRETTO-431均未设置RET融合阳性肺癌活动性脑膜转移的前瞻性专门队列;LIBRETTO-431将癌性脑膜炎列为排除标准。[6,7]
NCCN非小细胞肺癌指南V4.2026将普拉替尼和塞普替尼同列于RET融合阳性晚期或转移性非小细胞肺癌的一线Preferred(优选)分组,普拉替尼为2A类推荐,塞普替尼为1类推荐。1类基于高级别证据,2A类基于相对较低级别证据,两者均获专家组高度一致认可;这一差别本身不构成药物疗效排名,也不能据此认定塞普替尼的总体或颅内疗效优于普拉替尼。[8]
NCCN指南制定方法明确,除非另有说明,备选治疗的列名先后不代表专家组的偏好。[9] V4.2026的RET治疗算法没有针对脑转移另设必须优先使用塞普替尼的分支。[8]
2026年发表的ARROW最终分析中,15例基线具有可测量中枢神经系统转移灶的RET融合阳性非小细胞肺癌患者(14例接受过系统治疗)接受普拉替尼,8例获得颅内完全或部分缓解,颅内客观缓解率为53%(95% CI 27%–79%);缓解者的中位颅内缓解持续时间为14.8个月(95% CI 10.5个月至未达到)。[3]
ARROW为单臂研究;LIBRETTO-431比较的是塞普替尼与含铂化疗联合或不联合帕博利珠单抗,对照组并非普拉替尼。两项研究均未提供普拉替尼与塞普替尼颅内疗效优劣的直接比较结果。[3,10]
2026年ASCO公布的AcceleRET-Lung随机Ⅲ期研究共纳入223例RET融合阳性晚期或转移性非小细胞肺癌患者,比较一线普拉替尼(110例)与研究者选择的含铂标准治疗(113例,允许联合帕博利珠单抗)。主要终点为研究者按RECIST 1.1评估的无进展生存期(PFS)。[4,11]
普拉替尼组与标准治疗组的中位PFS分别为18.7个月和9.0个月,HR为0.59(95% CI 0.42–0.84;描述性P=0.003);客观缓解率分别为65.5%和41.6%,中位缓解持续时间分别为20.6个月和9.7个月。[4,11] 研究提前终止后,修订方案将疗效分析调整为描述性分析,不再实施原计划的正式假设检验。[11]
在安全性人群中,普拉替尼组(108例)与标准治疗组(104例)的感染发生率分别为71.3%和51.9%,感染死亡分别为8例(7.4%)和0例。普拉替尼治疗期间应监测感染征象与症状。[1,4]
[1] Rigel Pharmaceuticals, Inc. GAVRETO (pralsetinib) capsules, for oral use: Full Prescribing Information. Revised December 2025.
[2] Eli Lilly and Company. RETEVMO (selpercatinib) capsules and tablets, for oral use: Full Prescribing Information. Revised July 2026.
[3] Besse B, Subbiah V, Curigliano G, et al. Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion–Positive Non–Small Cell Lung Cancer. Journal of Clinical Oncology. 2026;44(13):1190–1197. DOI: 10.1200/JCO-25-01489.
[4] Popat S, Besse B, Calles A, et al. Efficacy and safety of pralsetinib as first-line treatment of RET fusion–positive advanced or metastatic non–small cell lung cancer (NSCLC): The phase 3 AcceleRET-Lung study. 2026 ASCO Annual Meeting. Journal of Clinical Oncology. 2026;44(16_suppl):8504. DOI: 10.1200/JCO.2026.44.16_suppl.8504.
[5] European Medicines Agency. Withdrawal assessment report for Gavreto (pralsetinib) (II-0002-G). 2023. EMA/45270/2023.
[6] Eli Lilly and Company. LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy with or without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer. Clinical Protocol J2G-MC-JZJC(e). 15 August 2023. NCT04194944.
[7] Eli Lilly and Company. A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001). Clinical Protocol LOXO-RET-17001 (J2G-OX-JZJA), Version 12.0. 15 August 2023. NCT03157128.
[8] Riely GJ, Wood DE, Aisner DL, et al. Non–Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. Journal of the National Comprehensive Cancer Network. 2026;24(4):e260017. DOI: 10.6004/jnccn.2026.0017.
[9] Pluchino LA, D’Amico TA. National Comprehensive Cancer Network Guidelines: Who Makes Them? What Are They? Why Are They Important? The Annals of Thoracic Surgery. 2020;110(6):1789–1795. DOI: 10.1016/j.athoracsur.2020.03.022.
[10] Zhou C, Solomon B, Loong HH, et al. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC. New England Journal of Medicine. 2023;389:1839–1850. DOI: 10.1056/NEJMoa2309457.
[11] F. Hoffmann-La Roche Ltd. A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer. Protocol BO42864, Version 6. 23 October 2024. NCT04222972.
温馨提示:本文仅供医学药学专业人士阅读。